Chicago, Illinois – Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of its global XTMAB16 Study in pulmonary sarcoidosis, an immune-mediated inflammatory disorder with few available treatment options. The dose-ranging study successfully enrolled 39...
Latest News
CHICAGO – Xentria Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all requirements and can proceed with initiation of the planned Phase 1 clinical trial of XTMAB-16....
CHICAGO – Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris. At the special meeting of Xeris stockholders held on September 14, 2021, approximately 97% of the shares voted were...
XNK Therapeutics will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. The proof of concept study is to determine the feasibility to expand and activate NK cells from patients with AML using XNK’s platform. The...
STOCKHOLM – XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated...
CALGARY, Alberta — XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in...
BUFFALO, NY – A new research paper was published in Aging, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.” X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of...
MARKHAM, Canada – Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting. With this approval, XTANDI becomes the first and only androgen receptor pathway inhibitor (ARPI) approved for use with or without a GnRH...
Rare diseases are not so rare. While a single rare disease may only affect a small proportion of the population, as many as 10% of Americans live with rare diseases, and most of those 30 million people have limited or no treatments and lack access to expert care. Now, Yale...
New Haven, Conn. — Lissencephaly is a spectrum of rare, genetic disorders in which the brain fails to develop its hallmark folds. The disorders are often associated with seizures and intellectual disability and currently there are no available treatments. A new Yale study, however, has identified a molecular mechanism that...